B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens - PubMed (original) (raw)
Review
B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens
Nicholas Chiorazzi et al. Ann N Y Acad Sci. 2005 Dec.
Abstract
B-Cell chronic lymphocytic leukemia (B-CLL) is an incurable disease that is relatively common among aging Caucasians. Patients with this leukemia can be divided into prognostic categories using clinical staging parameters, as well as molecular features [presence or absence of IgVH mutations in rearranged VHDJH segments that code for the leukemic B cell's receptor for antigen (BCR)]. In addition, the deduced amino acid structure of the BCRs from patients that fall into different prognostic categories is shared, to varying degrees, within these groups. In this paper, the molecular features of the genes that code for the BCRs of B-CLL patients are reviewed, and these are compared to antibodies of known specificity. These comparisons suggest that the BCRs of many cases resemble autoantibodies, and in some cases, antibodies to microbial antigens. Antigen-binding analyses confirm these impressions, and also indicate that polyreactivity appears to distinguish cases with worse clinical outcomes differ from those with better outcomes. The persistence of autoreactivity and polyreactivity is somewhat surprising, because IgV DNA sequence analyses suggest that many of the B cells that become leukemic have undergone one form or another of receptor editing. Thus, B-CLL appears to be a disease of B-cell clones that have undergone various types of receptor reconfiguration and yet retain inappropriate antigen-binding properties.
Similar articles
- From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity.
Ghia P, Scielzo C, Frenquelli M, Muzio M, Caligaris-Cappio F. Ghia P, et al. Autoimmun Rev. 2007 Dec;7(2):127-31. doi: 10.1016/j.autrev.2007.02.014. Epub 2007 Mar 22. Autoimmun Rev. 2007. PMID: 18035322 Review. - Role of the B-cell receptor in chronic lymphocytic leukemia: where do we stand?
Fais F, Bruno S, Ghiotto F. Fais F, et al. Ital J Anat Embryol. 2010;115(1-2):79-84. Ital J Anat Embryol. 2010. PMID: 21072994 Review. - B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor.
Chiorazzi N, Ferrarini M. Chiorazzi N, et al. Annu Rev Immunol. 2003;21:841-94. doi: 10.1146/annurev.immunol.21.120601.141018. Epub 2001 Dec 19. Annu Rev Immunol. 2003. PMID: 12615894 Review. - B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, Petlickovski A, Efremov DG, Croce CM, Chiorazzi N. Yan XJ, et al. Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11713-8. doi: 10.1073/pnas.0604564103. Epub 2006 Jul 24. Proc Natl Acad Sci U S A. 2006. PMID: 16864779 Free PMC article. - B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia.
Allsup DJ, Kamiguti AS, Lin K, Sherrington PD, Matrai Z, Slupsky JR, Cawley JC, Zuzel M. Allsup DJ, et al. Cancer Res. 2005 Aug 15;65(16):7328-37. doi: 10.1158/0008-5472.CAN-03-1563. Cancer Res. 2005. PMID: 16103084
Cited by
- Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia.
Anderson LA, Landgren O, Engels EA. Anderson LA, et al. Br J Haematol. 2009 Nov;147(4):444-9. doi: 10.1111/j.1365-2141.2009.07849.x. Epub 2009 Sep 1. Br J Haematol. 2009. PMID: 19725826 Free PMC article. - The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA. Fiorcari S, et al. PLoS One. 2013 Dec 23;8(12):e83830. doi: 10.1371/journal.pone.0083830. eCollection 2013. PLoS One. 2013. PMID: 24376763 Free PMC article. - Editorial: Structure, Isotypes, Targets, and Post-translational Modifications of Immunoglobulins and Their Role in Infection, Inflammation and Autoimmunity.
Harb J, Wilson BS, Hermouet S. Harb J, et al. Front Immunol. 2020 Aug 7;11:1761. doi: 10.3389/fimmu.2020.01761. eCollection 2020. Front Immunol. 2020. PMID: 32849630 Free PMC article. No abstract available. - Accelerated development of chronic lymphocytic leukemia in New Zealand Black mice expressing a low level of interferon regulatory factor 4.
Ma S, Shukla V, Fang L, Gould KA, Joshi SS, Lu R. Ma S, et al. J Biol Chem. 2013 Sep 13;288(37):26430-40. doi: 10.1074/jbc.M113.475913. Epub 2013 Jul 29. J Biol Chem. 2013. PMID: 23897826 Free PMC article. - Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Rozovski U, et al. Leuk Lymphoma. 2018 Nov;59(11):2686-2691. doi: 10.1080/10428194.2018.1439167. Epub 2018 Feb 21. Leuk Lymphoma. 2018. PMID: 29465264 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources